Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects.

Ziauddeen H, Chamberlain SR, Nathan PJ, Koch A, Maltby K, Bush M, Tao WX, Napolitano A, Skeggs AL, Brooke AC, Cheke L, Clayton NS, Sadaf Farooqi I, O'Rahilly S, Waterworth D, Song K, Hosking L, Richards DB, Fletcher PC, Bullmore ET.

Mol Psychiatry. 2013 Dec;18(12):1287-93. doi: 10.1038/mp.2012.154. Epub 2012 Nov 13. Erratum in: Mol Psychiatry. 2014 Dec;19(12):1341.

2.

Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.

Chamberlain SR, Mogg K, Bradley BP, Koch A, Dodds CM, Tao WX, Maltby K, Sarai B, Napolitano A, Richards DB, Bullmore ET, Nathan PJ.

Psychopharmacology (Berl). 2012 Dec;224(4):501-9. doi: 10.1007/s00213-012-2778-x. Epub 2012 Jul 3.

PMID:
22752384
3.

Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people.

Cambridge VC, Ziauddeen H, Nathan PJ, Subramaniam N, Dodds C, Chamberlain SR, Koch A, Maltby K, Skeggs AL, Napolitano A, Farooqi IS, Bullmore ET, Fletcher PC.

Biol Psychiatry. 2013 May 1;73(9):887-94. doi: 10.1016/j.biopsych.2012.10.022. Epub 2012 Dec 14.

4.

Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating.

Giuliano C, Robbins TW, Nathan PJ, Bullmore ET, Everitt BJ.

Neuropsychopharmacology. 2012 Nov;37(12):2643-52. doi: 10.1038/npp.2012.128. Epub 2012 Jul 18.

5.

The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects.

Ziauddeen H, Nathan PJ, Dodds C, Maltby K, Miller SR, Waterworth D, Song K, Warren L, Hosking L, Zucchetto M, Bush M, Johnson LV, Sarai B, Mogg K, Bradley BP, Richards DB, Fletcher PC, Bullmore ET.

J Clin Pharmacol. 2013 Oct;53(10):1078-90. doi: 10.1002/jcph.110. Epub 2013 Aug 11.

6.

Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist.

Ignar DM, Goetz AS, Noble KN, Carballo LH, Stroup AE, Fisher JC, Boucheron JA, Brainard TA, Larkin AL, Epperly AH, Shearer TW, Sorensen SD, Speake JD, Hommel JD.

J Pharmacol Exp Ther. 2011 Oct;339(1):24-34. doi: 10.1124/jpet.111.180943. Epub 2011 Jun 28.

7.

Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist.

Nathan PJ, O'Neill BV, Bush MA, Koch A, Tao WX, Maltby K, Napolitano A, Brooke AC, Skeggs AL, Herman CS, Larkin AL, Ignar DM, Richards DB, Williams PM, Bullmore ET.

J Clin Pharmacol. 2012 Apr;52(4):464-74. doi: 10.1177/0091270011399577. Epub 2011 May 24.

PMID:
21610207
8.

Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.

Ziauddeen H, Nestor LJ, Subramaniam N, Dodds C, Nathan PJ, Miller SR, Sarai BK, Maltby K, Fernando D, Warren L, Hosking LK, Waterworth D, Korzeniowska A, Win B, Richards DB, Vasist Johnson L, Fletcher PC, Bullmore ET.

Neuropsychopharmacology. 2016 Oct;41(11):2647-57. doi: 10.1038/npp.2016.60. Epub 2016 Apr 25. Erratum in: Neuropsychopharmacology. 2018 Mar;43(4):927.

9.

The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours.

Kelly E, Mundell SJ, Sava A, Roth AL, Felici A, Maltby K, Nathan PJ, Bullmore ET, Henderson G.

Psychopharmacology (Berl). 2015 Jan;232(1):305-14. doi: 10.1007/s00213-014-3666-3. Epub 2014 Jun 29.

10.

Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498.

Nathan PJ, Bush MA, Tao WX, Koch A, Davies KM, Maltby K, O'Neill BV, Napolitano A, Skeggs AL, Brooke AC, Richards DB, Williams PM, Bullmore ET.

J Clin Pharmacol. 2012 Oct;52(10):1456-67. Epub 2011 Dec 12.

PMID:
22162534
11.

Attenuation of cocaine and heroin seeking by μ-opioid receptor antagonism.

Giuliano C, Robbins TW, Wille DR, Bullmore ET, Everitt BJ.

Psychopharmacology (Berl). 2013 May;227(1):137-47. doi: 10.1007/s00213-012-2949-9. Epub 2013 Jan 9.

12.

Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial.

Faris PL, Kim SW, Meller WH, Goodale RL, Oakman SA, Hofbauer RD, Marshall AM, Daughters RS, Banerjee-Stevens D, Eckert ED, Hartman BK.

Lancet. 2000 Mar 4;355(9206):792-7.

PMID:
10711927
13.

The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.

Ripley TL, Sanchez-Roige S, Bullmore ET, Mugnaini M, Maltby K, Miller SR, Wille DR, Nathan P, Stephens DN.

Psychopharmacology (Berl). 2015 Sep;232(18):3431-41. doi: 10.1007/s00213-015-3995-x. Epub 2015 Jul 5.

14.

The Novel μ-Opioid Receptor Antagonist GSK1521498 Decreases Both Alcohol Seeking and Drinking: Evidence from a New Preclinical Model of Alcohol Seeking.

Giuliano C, Goodlett CR, Economidou D, García-Pardo MP, Belin D, Robbins TW, Bullmore ET, Everitt BJ.

Neuropsychopharmacology. 2015 Dec;40(13):2981-92. doi: 10.1038/npp.2015.152. Epub 2015 Jun 5.

15.

A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder.

Arnold LM, McElroy SL, Hudson JI, Welge JA, Bennett AJ, Keck PE.

J Clin Psychiatry. 2002 Nov;63(11):1028-33.

PMID:
12444817
16.

A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.

Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, Godoy-Matos A, Morgan C, Zanella MT, Coutinho W.

Arch Gen Psychiatry. 2003 Nov;60(11):1109-16.

PMID:
14609886
17.

Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial.

McElroy SL, Hudson JI, Malhotra S, Welge JA, Nelson EB, Keck PE Jr.

J Clin Psychiatry. 2003 Jul;64(7):807-13.

PMID:
12934982
18.

From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour.

Nathan PJ, Bullmore ET.

Int J Neuropsychopharmacol. 2009 Aug;12(7):995-1008. doi: 10.1017/S146114570900039X. Epub 2009 May 12. Review.

PMID:
19433009
19.

Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans.

Rabiner EA, Beaver J, Makwana A, Searle G, Long C, Nathan PJ, Newbould RD, Howard J, Miller SR, Bush MA, Hill S, Reiley R, Passchier J, Gunn RN, Matthews PM, Bullmore ET.

Mol Psychiatry. 2011 Aug;16(8):826-35, 785. doi: 10.1038/mp.2011.29. Epub 2011 Apr 19.

20.

Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial.

McElroy SL, Arnold LM, Shapira NA, Keck PE Jr, Rosenthal NR, Karim MR, Kamin M, Hudson JI.

Am J Psychiatry. 2003 Feb;160(2):255-61. Erratum in: Am J Psychiatry. 2003 Mar;160(3):612.

PMID:
12562571

Supplemental Content

Support Center